Do pharma and biotech patents qualify for the Cyprus IP Box?

Yes. Patents are a core qualifying asset. Income from active pharmaceutical ingredients, formulations, methods of use and other patented life-sciences IP can be taxed at an effective rate as low as ~3% in 2026, in proportion to the R&D you fund.

Do orphan-drug designations and SPCs qualify?

Yes. Orphan-drug designations qualify, and income earned during the EU market-exclusivity period is qualifying IP income. Supplementary protection certificates (SPCs), which extend patent protection on approved products, also qualify for the period they cover.

Does genetic and plant-breeder IP qualify?

Yes. Plant-breeder and genetic IP are qualifying assets under the Cyprus IP Box, alongside patents and utility models. Marketing intangibles such as brand names do not qualify.

What if our clinical R&D is done abroad?

R&D outsourced to unrelated third parties counts as qualifying expenditure even if performed abroad — the disqualifier is the relationship, not the location. R&D bought from related group companies does not count and lowers the nexus ratio.

For pharma, biotech & life sciences

The Cyprus IP Box for pharma, biotech & life sciences

Patents, orphan-drug designations, SPCs and other protected life-sciences IP qualify for the Cyprus IP Box, so companies that own and develop this IP can tax qualifying profit at an effective rate as low as ~3% in 2026.

Book your free IP Box assessment ← Full Cyprus IP Box guide

Why it fits

Why pharma & biotech companies qualify

The Cyprus IP Box covers patents, utility models, orphan-drug designations, plant-breeder and genetic IP, and supplementary protection certificates (SPCs). Income earned during a patent's life, an orphan drug's market-exclusivity period, or an SPC extension is qualifying IP income. As always, the benefit follows the R&D you fund yourself or outsource to unrelated parties.

Patents, SPCs, orphan-drug designations and genetic/plant IP qualify.
Income during exclusivity and SPC-extension periods qualifies.
In-house or unrelated-party R&D maximises the nexus ratio.
Capital gains on the disposal of qualifying IP are tax-exempt.

Effective tax rate for an owner-developed SaaS

~3%

15% corporate tax on just 20% of qualifying profit (2026).

Estimate your rate →

What counts

Which life-sciences income qualifies

Income from your qualifying patented and protected IP, less the direct costs of earning it.

Royalties & licence fees

Payments to use your patents, formulations or processes.

IP embedded in product price

The share of a product's price reflecting your patented IP.

Gains on IP disposal

Capital gains from selling qualifying IP are fully exempt.

Pure resale or unrelated trading income does not qualify, and marketing IP (brands, trademarks) is always excluded.

Who it's for

Built for life sciences

Pharma & drug development

APIs, formulations, methods of use and orphan drugs.

Biotech & genetics

Genetic material, plant-variety rights and bio-processes.

Medical devices

Patented devices and the software embedded in them.

Diagnostics & healthtech

Proprietary diagnostics and protected healthtech IP.

Answers

Pharma & biotech FAQ

Estimate your effective rate Check if you qualify first How to apply & what it costs Read the full Cyprus IP Box guide

Get started

Talk to a Cyprus IP Box specialist.

Book a free, no-obligation assessment. We'll confirm whether you qualify, estimate your effective rate, and give you a fixed quote — confidentially, usually within one business day.

Prefer to message us?

WhatsApp Viber

Reviewed by a Cyprus-admitted advocate · Last updated 21 June 2026.